The device was developed by a team led by Professor Song Ih Ahn of the Department of Mechanical Engineering at KAIST, in collaboration with researchers at Sungkyunkwan University, CHA Bundang Medical Center, and CHA University. Their work addresses a central problem in glioblastoma treatment: the tumor is not an isolated mass of malignant cells. It exists within a highly complex brain environment shaped by blood vessels, astrocytes, immune cells, and the altered barrier that forms around the tumor. Because anticancer drugs must cross this barrier before reaching tumor cells, the same concentration of a drug may produce very different biological effects depending on how permeable or restrictive that barrier is in an individual patient.

The healthy blood–brain barrier is formed largely by specialized brain endothelial cells that line blood vessels and tightly regulate the movement of molecules between the bloodstream and neural tissue. These cells are supported by astrocytes and other components of the neurovascular unit. Tight junctions between endothelial cells limit the passage of many substances, including numerous therapeutic compounds. When glioblastoma develops, the surrounding vascular system becomes abnormal. The resulting blood–brain tumor barrier may contain regions that are more permeable than a healthy barrier, while other areas remain highly restrictive. This uneven and patient-specific architecture can influence drug delivery, tumor metabolism, resistance mechanisms, and the survival of malignant cells beyond what can be predicted from tumor genetics alone.

To recreate this environment, the researchers constructed a microfluidic chip containing separate but closely connected channels. Brain microvascular endothelial cells, known as HBMECs, were placed in an upper vascular channel, while astrocytes and patient-derived glioblastoma cells were cultured in a lower tissue channel. The arrangement allows researchers to observe how the two compartments interact while measuring the movement of drugs across the engineered barrier. Microfluidic systems use precisely controlled chambers and fluid pathways that can reproduce aspects of blood flow, concentration gradients, and tissue organization on a small scale. The design can also accommodate perivascular and immune cells, creating the possibility of modeling an even broader range of biological interactions within the tumor microenvironment.

The team used tumor cells obtained from three glioblastoma patients to create individual blood–brain tumor barrier models. Each patient had the same IDH-wildtype classification and the same MGMT promoter methylation status, a biomarker commonly used to estimate sensitivity to temozolomide, one of the standard drugs used against glioblastoma. On the basis of conventional clinical testing, the patients might therefore have been expected to respond in broadly similar ways. The researchers then exposed the patient-specific chips to temozolomide and bevacizumab, an antibody that targets vascular endothelial growth factor and is used to influence tumor-associated blood vessels. The experiments allowed the team to evaluate both the ability of the drugs to cross the engineered barrier and their effects on the tumor cells behind it.

The results revealed differences that were not apparent from the shared genetic and biomarker profiles. The three models showed distinct barrier properties, including differences in permeability and electrical resistance, measurements that reflect how tightly the endothelial layer controls transport. They also displayed differences in gene expression and in their responses to the two anticancer agents. In practical terms, the same drug encountered a different biological gateway in each chip. A treatment could therefore be affected not only by whether the tumor cells were intrinsically sensitive to the drug, but also by how efficiently the patient-specific vascular barrier allowed the drug to reach them and how the surrounding cells altered the tumor’s behavior.

The researchers compared the chip findings with the actual clinical courses of the three patients, including progression-free survival and post-progression survival. According to the team, the on-chip barrier characteristics and drug responses closely matched the outcomes observed in the patients. The comparison suggests that the engineered models captured clinically meaningful features of each person’s disease, despite the small number of cases. The result is important because conventional testing often focuses on the cancer cell itself, while the chip evaluates the complete route a treatment must follow: from the vascular channel, across the tumor-associated barrier, and into the tissue containing malignant cells and supporting cells.

The platform could eventually become a tool for testing several therapies from a single patient’s tumor sample before a treatment decision is made. Researchers could expose parallel chips to different drug combinations, doses, or emerging compounds and compare the resulting tumor responses under conditions that more closely resemble the patient’s own disease. Such testing would not replace clinical trials or medical judgment, and the current findings require validation in a substantially larger patient population. The tumors grown on a chip also cannot reproduce every feature of a living brain, including long-range immune responses, systemic drug metabolism, and the full three-dimensional complexity of a patient’s tumor. Nevertheless, incorporating the blood–brain tumor barrier represents a significant advance over models that test drugs only on isolated cancer cells.

The study’s authors say the same approach could also assist pharmaceutical research by providing a human-relevant system for evaluating new drug candidates and studying why treatments fail. The inclusion of perivascular and immune components may make it possible to investigate how blood vessels and immune cells contribute to resistance, invasion, and recurrence. Minsu Ryoo of KAIST and Gaeun Lee of Sungkyunkwan University served as co-first authors. The findings were published in Small on June 27, 2026, and were selected for the journal’s Front Cover. Professor Ahn described the work as a platform for reproducing patient-derived tumor cells together with the blood–brain tumor barrier, with the longer-term goal of developing personalized treatment strategies and a preclinical system for new drug development. If future studies confirm its reproducibility and predictive accuracy, the chip could help move glioblastoma care toward a model in which treatment is selected not only by what a tumor is, but also by the living barrier that determines whether medicine can reach it.

Subject of Research: Patient-specific blood–brain tumor barrier-on-a-chip models for predicting glioblastoma treatment responses

Article Title: Human Blood-Brain Tumor Barrier on a Chip to Investigate Personalized Treatment for Glioblastoma Patients

News Publication Date: 18-Aug-2026

Web References: KAIST; https://doi.org/10.1002/smll.202506712

References: Small, published 27-Jun-2026; DOI: 10.1002/smll.202506712

Image Credits: KAIST

Keywords: glioblastoma, blood–brain tumor barrier, blood–brain barrier, organ-on-a-chip, microfluidics, personalized medicine, temozolomide, bevacizumab, drug response prediction, brain cancer, tumor microenvironment, precision oncology

Glioblastoma multiforme (GBM) has presented a formidable challenge in neuro-oncology, primarily due to its highly invasive nature, heterogeneity, and immunosuppressive tumor microenvironment (TME). Previous attempts to employ immunotherapy in GBM have often faltered because the adaptive immune response in the brain is uniquely regulated, and the tumor itself frequently evades immune detection. However, this new research harnesses the polyclonal repertoire of tumor-reactive lymphocytes naturally infiltrating glioblastoma tissues, suggesting a paradigm shift where the immune system’s intrinsic capacity is amplified and redirected for therapeutic benefit.

At the heart of this approach lies the principle of isolating TILs directly from patient tumor samples, followed by their ex vivo polyclonal expansion under conditions that preserve their tumor specificity and effector functions. Unlike monoclonal strategies that rely on single antigen targets and risk immune escape, polyclonal expansion capitalizes on the diverse array of tumor antigens recognized by various T cell clones. This diversity is crucial in GBM, where antigenic heterogeneity and mutational burden complicate targeted therapies.

The study meticulously characterizes the phenotypic and functional attributes of these expanded TIL populations, demonstrating their robust cytotoxic capacity against autologous tumor cells in vitro. Importantly, the investigators employed advanced flow cytometry and single-cell sequencing technologies to elucidate the clonality and transcriptional profiles of the T cells, revealing a rich landscape of tumor-reactive subsets bearing activation markers such as CD137 and PD-1. These features underscore the functional readiness of the TILs for therapeutic deployment.

Moreover, the researchers optimized culture protocols incorporating cytokines like IL-2 and IL-15 to maintain T cell viability and enhance expansion efficiency, balancing proliferation with the retention of a less differentiated, memory-like phenotype. This aspect is critical because terminally differentiated T cells often suffer from exhaustion, limiting their persistence and antitumor efficacy upon infusion. By maintaining the TILs’ proliferative potential and functional fitness, the protocol lays the groundwork for durable therapeutic responses.

Another remarkable facet of this study involves the validation of TIL specificity through functional assays measuring interferon-gamma (IFN-γ) release and cytolysis. The polyclonally expanded lymphocytes exhibited potent tumor cell killing without significant reactivity against nonmalignant brain cells, an essential safety consideration given the delicate neural environment. This tumor-selective cytotoxicity implies that the approach may minimize off-target effects often associated with systemic immunotherapies.

Perhaps most striking is the personalized nature of this cell therapy. Because TILs are harvested directly from each patient’s tumor, the resulting cellular product inherently embodies the unique antigenic landscape of their cancer. This individualized targeting is likely to overcome the heterogeneous mutation profiles that thwart standardized treatments. It also offers a compelling solution to immune evasion mechanisms deployed by glioblastoma, as the broad-spectrum TIL repertoire can adapt to multiple tumor epitopes simultaneously.

The translational potential of this study is underscored by the researchers’ demonstration of in vivo efficacy in orthotopic glioblastoma models. Mice receiving adoptively transferred expanded TILs showed significant tumor regression and prolonged survival compared to controls, providing a proof-of-concept for clinical application. These promising preclinical results pave a path toward human trials, wherein such adoptive cell therapies could be integrated with existing treatment modalities such as surgery, radiotherapy, and checkpoint inhibitors.

This research also sheds light on the intricate interplay between tumor immunology and neurobiology. Understanding how TILs traffic to and survive within the central nervous system, a traditionally immune-privileged site, adds a valuable dimension to immunotherapy design. The ability to expand functional lymphocytes that can overcome the immune barriers imposed by the brain microenvironment is a testament to the evolution of immuno-oncology.

Furthermore, the integration of high-throughput sequencing data with functional assays offers a blueprint for biomarker development. Identifying signatures predictive of TIL expansion success or patient responsiveness will be instrumental in patient stratification and therapy customization. Such biomarkers could inform the selection of candidates most likely to benefit from TIL therapy while sparing others from ineffective treatments.

Despite these advances, challenges remain before this therapy reaches routine clinical use. Manufacturing scalability, regulatory hurdles, and ensuring durable TIL engraftment in patients are critical issues slated for future research. Intratumoral heterogeneity and the potential for immune suppression within glioblastoma also necessitate combination strategies, possibly combining TIL therapy with modulators of the TME or checkpoint blockade to fully unleash antitumor immunity.

Nonetheless, the implications of this research resonate beyond glioblastoma. The methodology for polyclonal TIL expansion and its cross-application to other solid tumors heralds a new era of cell-based immunotherapies that are more adaptable and precise. By leveraging the intrinsic immune repertoire, scientists are edging closer to truly personalized cancer treatments that harness the patient’s own biology rather than relying solely on synthetic drugs.

In summation, the study represents a milestone in neuro-oncology and immunotherapy, providing compelling evidence that functional tumor-reactive lymphocytes can be expanded ex vivo to produce potent, safe, and personalized cell products capable of combating glioblastoma. It captures the essence of next-generation therapies, where immunological nuance and personalized medicine converge to offer hope against a historically intractable cancer.

As the scientific community anticipates clinical trials based on these findings, the growing momentum in adoptive TIL therapy underscores the transformative potential of immunotherapy. This study not only expands our understanding of glioblastoma’s immunobiology but also charts a path forward for innovative treatments that could ultimately improve survival and quality of life for patients facing this devastating diagnosis.

The convergence of immunology, genomics, and cellular engineering exemplified in this research marks a pivotal advancement. By continuing to unravel the complexities of tumor-immune dynamics and refining TIL expansion protocols, precision immunotherapy for glioblastoma may soon transition from promising research to clinical reality, ushering in a new hope for patients worldwide.

Subject of Research: Polyclonal expansion of tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy.

Article Title: Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy.

Article References:
Maffezzini, M., Musio, S., Di Ianni, N. et al. Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy.
Nat Commun 16, 7279 (2025). https://doi.org/10.1038/s41467-025-62263-2

Image Credits: AI Generated